Loading
If most tumours escape a drug by the same back-up route, blocking that route from the start may prevent resistance rather than chase it.
For several targeted agents the dominant bypass is known in advance: MET amplification after EGFR inhibition, RTK and MAPK reactivation after KRAS G12C inhibition, and MEK reactivation after BRAF inhibition (which is why BRAF and MEK inhibitors are combined). Extending upfront combination logic requires tolerability, so intermittent scheduling or lower-dose partner agents should be part of the design.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for EGFR in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for EGFR in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Wrong doses.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Acquired resistance to every therapy.
Shares FLAURA2, FLAURA, ADAURA, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares MARIPOSA, Amivantamab, MET, Osimertinib.
Shares FLAURA2, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Too many combinations to test, Osimertinib.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Amivantamab, MET, Osimertinib.
Shares MARIPOSA, Amivantamab, MET, Osimertinib.